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enthusiasm for the stentless porcine valve was not supported by the
available data.
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REPLY
In Dr. Bloomfield’s letter discussing the Viewpoint (1) and
Commentary (2) recently published in the Journal, Dr. Bloomfield
notes that, in long-term follow-up of the Edinburgh Heart Valve
Trial (3), 1) mortality at 20 years did not differ between mechanical
and tissue prostheses; 2) owing to differences in rates of re-
operation, freedom from all valve-related complications was supe-
rior after mechanical mitral (but not aortic) valve replacement; and
3) over time, an increasing use of anticoagulant therapy was seen
after tissue valve replacement. Dr. Bloomfield concludes that
long-term follow-up of patients in randomized trials is the only
means by which differences between prostheses can be elucidated.
Equivalence of mortality at 20 years supports that, using this
end point, existing data (including those from the Edinburgh
Heart Valve Trial) do not favor one prosthesis type over another.
Freedom from all valve-related complications favors neither pros-
thesis type following aortic valve replacement, which comprises a
preponderance of valve replacement surgeries in the United States;
for both mitral and aortic valves, higher rates of re-operation after
tissue compared with mechanical valve replacement exemplifies an
inherent difference between prostheses. However, re-operation
may be an end point more universally feared by cardiologists than
by patients. Operative mortality for elective “re-do” valve replace-
ment is not substantially different from that for initial surgery.
Whereas some patients may wish to avoid re-operation at all costs,
others are clearly willing, if given the option, to face the near-
certainty of additional surgery in order to avoid daily anticoagula-
tion. This argument is not obviated by an early experience showing
increasing requirement over time for anticoagulation due to atrial
fibrillation. Atrial fibrillation carries a lower thromboembolic risk
(and therefore requires less aggressive anticoagulation) compared
with mechanical mitral valve replacement. Moreover, earlier inter-
vention as well as newer medical therapies and surgical and
percutaneous procedures presently available for the treatment of
atrial arrhythmias can be expected to lower the need for additional
long-term anticoagulation compared with the cohort studied from
the 1970s.
The tenet of the previously published Viewpoint (1) is not that
long-term data are not desirable, but that for prosthetic valve
choices that are made today, pertinent long-term, randomized data
do not (and will never) exist. Although Dr. Bloomfield and his
co-investigators (3) are to be commended for their study, the data
as they relate to current decisions in prosthetic valve surgery are
moot. In 2004, neither the Bjork-Shiley nor the original Hancock
valve is available for implantation. Future randomized studies are
unrealistic, and even if performed, valve technology would again
have evolved by the time long-term data became available. Rather
than attempting to extrapolate to current practice “tissue versus
mechanical” data from valves that are obsolete and in some cases
known to be poorly representative of currently available prostheses,
this author asks the clinician to understand the limitations of these
data, and to recognize that the gradual and continuing advances
made in heart valve prostheses make a demand for only long-term,
randomized data unrealistic and therefore unwise.
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Increased Randomness of
Heart Rate Could Explain
Increased Heart Rate Variability
Preceding Onset of Atrial Fibrillation
The recent study in JACC by Amar et al. (1) describes significant
increases in heart rate variability (HRV) in the period preceding
the onset of atrial fibrillation (AF) in postoperative patients. This
increase in HRV is interpreted by the investigators as reflecting
increased parasympathetic and sympathetic activity. Whereas this
is a possible explanation, another equally plausible explanation
requires testing. We propose that the increase in HRV is due to an
increase in the randomness of the heart-period signal, associated
with a marked increase in sympathetic activation. This would be
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